Fabry disease is caused by deficient activity of α-galactosidase A, an enzyme that hydrolyzes the terminal α-galactosyl moieties from glycolipids and glycoproteins, and subsequent accumulation of glycosphingolipids, mainly globotriaosylceramide (Gb), globotriaosylsphingosine (lyso-Gb), and galabiosylceramide. However, there is no known link between these compounds and disease severity. In this study, we compared Gb isoforms (various fatty acids) and lyso-Gb analogs (various sphingosine modifications) in two strains of Fabry disease mouse models: a pure C57BL/6 (B6) background or a B6/129 mixed background, with the latter exhibiting more prominent cardiac and renal hypertrophy and thermosensation deficits.
View Article and Find Full Text PDF